Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Covington
Chinese Patent Office
Express Scripts
Colorcon
Cantor Fitzgerald

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,273,341

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,273,341
Title:Antiviral compounds
Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Guo; Hongyan (Foster City, CA), Kato; Darryl (Foster City, CA), Kirschberg; Thorsten A. (Foster City, CA), Liu; Hongtao (Foster City, CA), Link; John O. (Foster City, CA), Mitchell; Michael L. (Foster City, CA), Parrish; Jay P. (Foster City, CA), Graupe; Michael (Foster City, CA), Sun; Jianyu (Foster City, CA), Taylor; James (Foster City, CA), Bacon; Elizabeth M. (Foster City, CA), Canales; Eda (Foster City, CA), Cho; Aesop (Foster City, CA), Kim; Choung U. (Foster City, CA), Cottell; Jeromy J. (Foster City, CA), Desai; Manoj C. (Foster City, CA), Halcomb; Randall L. (Foster City, CA), Krygowski; Evan S. (Foster City, CA), Lazerwith; Scott E. (Foster City, CA), Liu; Qi (Foster City, CA), Mackman; Richard (Foster City, CA), Pyun; Hyung-Jun (Foster Cit, CA), Saugier; Joseph H. (Foster City, CA), Trenkle; James D. (Foster City, CA), Tse; Winston C. (Foster City, CA), Vivian; Randall W. (Foster City, CA), Schroeder; Scott D. (Foster City, CA), Watkins; William J. (Foster City, CA), Xu; Lianhong (Foster City, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:13/291,977
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,273,341
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,273,341

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir TABLET;ORAL 205834-001 Oct 10, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up FOR THE TREATMENT OF HEPATITIS C ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,273,341

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 3622 ➤ Sign Up
Argentina 076765 ➤ Sign Up
Australia 2010249043 ➤ Sign Up
Brazil 122014012810 ➤ Sign Up
Brazil 122014013631 ➤ Sign Up
Brazil PI1010795 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
US Department of Justice
UBS
Colorcon
Johnson and Johnson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.